Short answer
ANAPTYSBIO, INC (ANAB) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $26M (down 8.0% year over year) with net income of −$53M.
Q1 2026 key financials · XBRL
- Revenue
- $26M
- −8.0% YoY
- Net income
- −$53M
- −34.5% YoY
- Operating margin
- -135.5%
- EPS (diluted)
- −$1.84
- −43.8% YoY
Source: XBRL data from the ANAPTYSBIO, INC (ANAB) Q1 2026 10-Q on SEC EDGAR. USD.
ANAPTYSBIO, INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered legal risk: Delaware Chancery Court litigation against Tesaro and GSK filed November 20, 2025
- Collaboration risk: GSK terminated the TIM-3 antagonist program in October 2025, eliminating future milestones and royalties
- Regulatory risk: Additional post-approval studies or trials could be required for Jemperli
- Market risk: Jemperli faces competition from Keytruda and other oncology therapies
- Revenue concentration risk: Royalties from Jemperli expected to comprise substantially all future revenues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAPTYSBIO, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.